Hsbc Holdings PLC Fibrogen Inc Call Options Transaction History

Hsbc Holdings PLC

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q1 2018 May 11, 2018	SELL	$45.35 - $61.65 $1.13 Million - $1.54 Million	-25,000 Reduced 62.5%	15,000 $691,000
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $1.34 Million - $2.16 Million	40,000	40,000 $2.15 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.